Stockysis — AI-Powered Stock News & Sentiment Analysis

B. Riley Securities Maintains Buy on Capricor Therapeutics, Raises Price Target to $63

Benzinga Newsdesk www.benzinga.com Positive 82.8%

Neg 0% Neu 0% Pos 82.8%

B. Riley Securities analyst Madison El-Saadi maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price target from $50 to $63.

Comments

No comments yet. Be the first!